Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CC-99677 in Healthy Japanese Adults
NCT04958291Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gamcemetinib in ankylosing spondylitis (AS) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Incidence of Adverse Events (AEs). Started Aug 2021; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04958291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958291.